Table 2 Data of subjective symptoms and adverse effects or serious adverse events in the included studies
Author | Year | Region | Total No. and No. of events | Hydroxychloroquine | Placebo |
|---|---|---|---|---|---|
Gottenberg J.E. et al. | 2014 | France | Total patients | 56 | 64 |
No. of dry mouth | 50 | 53 | |||
No. of improved (%) | 21 (42.0) | 22 (41.5) | |||
No. of dry eyes | 50 | 53 | |||
No. of improved (%) | 21 (42.0) | 22 (41.5) | |||
No. of pain | 46 | 47 | |||
No. of improved (%) | 25 (54.3) | 17 (36.2) | |||
No. of fatigue | 48 | 50 | |||
No. of improved (%) | 11 (22.9) | 14 (28.0) | |||
No. of adverse effects | - | - | |||
No. of serious adverse events | 2 | 3 | |||
Fox R.I. et al. | 1996 | USA | Total patients | 50 | - |
No. of dry mouth | 40 | - | |||
No. of improved (%) | 23 (57.5) | - | |||
No. of dry eyes | 40 | - | |||
No. of improved (%) | 25 (62.5) | - | |||
No. of pain | 40 | - | |||
No. of improved (%) | 17 (42.5) | - | |||
No. of fatigue | 40 | - | |||
No. of improved (%) | 15 (37.5) | - | |||
No. of adverse effects | 8 | - | |||
No. of serious adverse events | - | - | |||
Kruize A.A. et al. | 1993 | Netherlands | Total patients | 10 | 9 |
No. of dry mouth | 6 | 6 | |||
No. of improved (%) | 2 (33.3) | 3 (50.0) | |||
No. of dry eyes | 7 | 6 | |||
No. of improved (%) | 3 (42.9) | 4 (66.7) | |||
No. of pain | 2 | 4 | |||
No. of improved (%) | 1 (50.0) | 1 (25.0) | |||
No. of fatigue | 6 | 6 | |||
No. of improved (%) | 4 (66.7) | 5 (83.3) | |||
No. of adverse effects | 1 | 0 | |||
No. of serious adverse events | - | - |